Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

Inclusion Criteria: * Have underlying HeFH and/or a history of ASCVD or multiple ASCVD risk factors * On maximally tolerated lipid-modifying therapy as an adjunct to a diet and lifestyle modifications * LDL-C ≥ 70 mg/dL * Triglycerides \< 500 * Estimated glomerular filtration rate ≥ 15 mL/min/1.73 m2 Exclusion Criteria: * History of New York Heart Association (NYHA) class III or IV heart failure of left ventricular ejection fraction \<30% * Hospitalized for heart failure within the last 5 years * Myocardial infarction, stroke, non-elective coronary revascularization or hospitalization for unstable angina or chest pain in the last 3 months * Uncontrolled severe hypertension * Diagnosis of homozygous FH * Liver disease * HbA1c ≥ 10.0% or fasting glucose ≥ 270 mg/dL * Thyroid-stimulating hormone \>1.5 x upper limit of normal (ULN) * History of malignancy * Creatinine kinase (CK) \>3 X ULN * Alcohol abuse * Treatment with investigational product * Treatment with gemfibrozil or ezetimibe * Previous participation in a trial evaluating obicetrapib * Known allergy to study drugs, placebo or excipients in study drugs of placebo * Other condition that would interfere with the conduct of the study